BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 UBS Global Life Sciences Conference, to be held September 20 - 22, 2010 in New York City. Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer, will present a 30 minute corporate overview on September 20 at 11:30 AM ET.
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcast will also be available on the Company's website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Director, Corporate Communications
KEYWORDS: United States North America Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Other Science Science